JAMA Health Forum最新文献

{"title":"Health Care Outcomes of Homelessness Prevention Programs in Veterans Experiencing Housing Instability.","authors":"Richard E Nelson, Alec B Chapman, Ann Elizabeth Montgomery, Ying Suo, Atim Effiong, Christa Shorter, Tom Greene, Jack Tsai, Lillian Gelberg, Stefan G Kertesz, Thomas Byrne","doi":"10.1001/jamahealthforum.2025.6417","DOIUrl":"10.1001/jamahealthforum.2025.6417","url":null,"abstract":"<p><strong>Importance: </strong>Homelessness is associated with negative health outcomes and increased health care costs. The United States Department of Veterans Affairs (VA) Supportive Services for Veteran Families (SSVF) program provides housing-related financial assistance and other supports to veterans experiencing housing instability; however, little is known regarding short-term assistance interventions with a prevention focus.</p><p><strong>Objective: </strong>To estimate potential impacts of the SSVF program in mortality and health care cost outcomes over 3 years following program entry.</p><p><strong>Design, setting, and participants: </strong>Using observational data, outcomes were compared between veterans who enrolled in SSVF with those who did not for each month from October 2015 to December 2018. A propensity score for SSVF enrollment was calculated using observable characteristics including demographics, housing history, health care cost history, comorbidities, and geography. Using inverse probability of treatment weighting-a propensity score-based method that creates a pseudopopulation in which treatment groups are balanced on observed covariates-the potential impacts of SSVF enrollment in mortality were estimated using a Cox proportional hazards regression and health care costs with a generalized linear model over the 3 years following the trial index date. Data were from the VA electronic health record for a cohort of veterans receiving care in the VA system. Each trial drew on veterans with evidence of homelessness in structured and unstructured medical records during the previous month. Data were analyzed from November 1, 2023, to September 9, 2025.</p><p><strong>Exposure: </strong>The exposure was enrollment in the SSVF program, from the Homeless Management Information System data.</p><p><strong>Main outcome: </strong>The main outcomes were all-cause mortality and VA health care costs.</p><p><strong>Results: </strong>The cohort consisted of 693 383 patient-trials with 26 649 (3.8%) enrolling in SSVF (mean [SD] age, 52.7 [12.6] years; 89.6% male) and 666 734 (96.5%) in the no SSVF group (mean [SD] age, 53.8 [13.0] years; 90.8% male). Enrollment in SSVF was associated with a decrease in the risk of mortality (hazard ratio, 0.87; 95% CI, 0.82-0.92). In addition, enrollment in SSVF was associated with an increase in outpatient costs ($7534; 95% CI, $6767-$8302) and a decrease in inpatient costs (-$10 020; 95% CI, -$13 644 to -$6396).</p><p><strong>Conclusions and relevance: </strong>In this study, federal prevention solutions to homelessness were associated with improved health outcomes and lower inpatient costs, which should inform national policy debates within and beyond the VA.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256417"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tertiary Patents on Drugs Approved by the FDA.","authors":"Theodore W Teng, S Sean Tu, Helen Mooney, Liam Bendicksen, Sarah M E Gabriele, Olivier J Wouters, William B Feldman","doi":"10.1001/jamahealthforum.2025.5909","DOIUrl":"10.1001/jamahealthforum.2025.5909","url":null,"abstract":"<p><strong>Importance: </strong>Manufacturers of drug-device combinations, such as inhalers and injectable medications, often obtain patents not just on the active pharmaceutical ingredients of these products (primary patents) but also on other features, such as their formulations and methods of use (secondary patents) and delivery devices (tertiary patents). Courts, policymakers, and regulators have recently begun scrutinizing whether manufacturers may be improperly listing tertiary patents with the Food and Drug Administration (FDA) that lack claims on active pharmaceutical ingredients and whether such patents may be delaying generic competition. However, the full scope of patenting practices on drug-device combinations remains unknown.</p><p><strong>Objective: </strong>To analyze patent protection on small-molecule drugs approved by the FDA from 1986 to 2023 with 1 or more tertiary patents.</p><p><strong>Design, setting, and participants: </strong>In this retrospective cohort study of patenting practices on drug-device combinations, all patents listed in the FDA's Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book) were categorized (primary, secondary, or tertiary), and products with at least 1 tertiary patent were included. Analyses were performed between May 2024 and October 2025.</p><p><strong>Main outcomes and measures: </strong>The primary outcome of the study was the duration of expected patent protection on each product, measured from the time of approval until expiration of the last-to-expire patent. Added protection from tertiary patents that went beyond protection afforded by primary or secondary patents was also analyzed.</p><p><strong>Results: </strong>The FDA approved 331 products from 1986 to 2023 with 1 or more tertiary patents; 137 of 3241 patents (4.2%) listed on these products were primary patents, 1353 of 3241 were secondary patents (41.7%), and 1751 of 3241 were tertiary patents (54.0%). Among tertiary patents, 1047 of 1751 (59.8%) lacked claims making any mention of active pharmaceutical ingredients. The median (IQR) duration of expected patent protection among products in the cohort was 17.6 (14.4-21.2) years. There were 180 products (54.4%) that had tertiary patents extending periods of expected protection beyond other patents, and the median (IQR) duration of added protection was 7.5 (2.8-13.9) years.</p><p><strong>Conclusions and relevance: </strong>The findings of this cohort study suggest that policymakers and regulators should take steps to ensure that tertiary patents are not improperly listed in the Orange Book and that generic competition occurs in a timely fashion.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e255909"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12761334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To Improve US Life Expectancy, a New North Star Is Needed.","authors":"Marc N Gourevitch","doi":"10.1001/jamahealthforum.2025.6524","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.6524","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256524"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extreme Risk Protection Orders and Firearm and Nonfirearm Suicides in the US.","authors":"Timothy T Brown, Mark S Kaplan, Zhimeng Yan, Yunyu Xiao","doi":"10.1001/jamahealthforum.2025.6442","DOIUrl":"10.1001/jamahealthforum.2025.6442","url":null,"abstract":"<p><strong>Importance: </strong>Firearm suicides constitute a crisis in the US, accounting for more than half (55.4%) of all suicide deaths in 2023. Extreme Risk Protection Orders (ERPOs; ie, red flag laws) authorize temporary firearm removal from individuals deemed at high risk of harming themselves or others. While ERPOs are designed to reduce firearm-related suicides, whether they result in a net reduction in suicide deaths or shift firearm suicides to suicides by other methods remains an important but unresolved issue in determining their effectiveness.</p><p><strong>Objective: </strong>To determine the association of ERPOs with firearm suicides and nonfirearm suicides in states with sufficient postpolicy data and no confounding firearm legislation that may bias findings on ERPO outcomes.</p><p><strong>Design, setting, and participants: </strong>In this cohort study, 2-way difference-in-differences event study analyses were conducted using county-level data from 2012 to 2022. All states that passed ERPO laws alone, with no other new firearm laws, from 2018 to 2020, and had at least 1 year post-ERPO laws during which no new firearm laws were passed were investigated. All states that had no existing ERPO laws and passed no new firearm legislation from 2016 to 2022 were used for comparison. The model accounted for staggered treatment timing, treatment heterogeneity, and key methodological assumptions. Data were analyzed between February 6 and October 9, 2025.</p><p><strong>Exposure: </strong>State-level ERPO law passage.</p><p><strong>Main outcomes and measures: </strong>County-level annual firearm suicides and nonfirearm suicides per 100 000 population, derived from Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research.</p><p><strong>Results: </strong>This study examined county-level data from 4 states passing ERPO laws alone (Massachusetts, New Jersey, New Mexico, and Rhode Island) compared with 8 that did not (Alabama, Alaska, Michigan, Minnesota, Nebraska, North Carolina, Pennsylvania, and South Carolina). ERPO passage was associated with a mean reduction of 3.79 firearm suicides per 100 000 population after 1 year (95% CI, -6.74 to -0.83; P = .01), equivalent to an estimated 675 suicides. With regard to nonfirearm suicides, no association was found in the year ERPO laws were passed (0.41; 95% CI, -1.21 to 1.94; P = .60) or in the next year (-2.45; 95% CI, -6.84 to 1.93; P = .27).</p><p><strong>Conclusions and relevance: </strong>In this cohort study, ERPO laws in Massachusetts, New Jersey, New Mexico, and Rhode Island were associated with substantial reductions in firearm suicides, with no evidence of substitution with nonfirearm methods. These findings support ERPOs as targeted public health interventions to reduce firearm suicides without increasing suicides by other methods.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256442"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12859719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stakeholder Engagement for Hepatitis C Virus Elimination.","authors":"Louis P Garrison, Bruce C M Wang","doi":"10.1001/jamahealthforum.2025.6433","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.6433","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256433"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Medication Use During Medicaid Continuous Enrollment and Unwinding.","authors":"Benjamin N Rome, Jihye Han, Adrianna McIntyre, Aaron S Kesselheim, Benjamin D Sommers","doi":"10.1001/jamahealthforum.2025.5890","DOIUrl":"10.1001/jamahealthforum.2025.5890","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;During the COVID-19 pandemic, Medicaid enrollment increased because states suspended routine eligibility determinations. After this continuous enrollment provision ended in April 2023, millions of US individuals lost Medicaid coverage.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To measure how the unwinding of Medicaid enrollment was associated with changes in patients' use of health services, such as prescription medications.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;A cross-sectional study was carried out using interrupted time series analysis to compare changes in quarterly Medicaid enrollment and prescription medication use from 2018, quarter (Q) 1 through 2024, Q1. Data were analyzed from November 2024 to February 2025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;The onset of continuous enrollment provision (2020, Q2) and unwinding (2023, Q2).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The outcomes were quarterly state Medicaid enrollment and estimated number of reimbursed prescriptions. Log-transformed linear regression models were used to compare changes in state enrollment and prescriptions after continuous enrollment and unwinding, overall and stratified by states with different net enrollment changes and policies to protect patients during unwinding. Subsets of medications for certain chronic conditions and formulations primarily used by children were analyzed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In the quarter before the COVID-19 pandemic (2019, Q4), Medicaid enrollment was 71.4 million, and there were about 183.2 million prescriptions reimbursed by Medicaid programs. This included 59.1 million (32.3%) prescriptions treating chronic diseases, 30.3 million (16.5%) for acute conditions, and 15.0 million (8.2%) for other specified conditions. In 2023, Q2, enrollment peaked at 93.9 million (31.4% increase from baseline), and the number of prescriptions peaked at 212.6 million (16.1% increase from baseline). Enrollment increased by 2.42% (95% CI, 2.15%-2.70%) per quarter during continuous enrollment and decreased by 4.92% (95% CI, -6.12% to -3.70%) per quarter during unwinding. Concurrently, the number of prescriptions increased by 1.85% (95% CI, 1.21%-2.50%) per quarter and then decreased by 3.94% (95% CI, -5.73% to -2.11%) per quarter. Trends were similar for chronic disease medications and pediatric-specific formulations. States with the highest disenrollment during unwinding had the largest decreases in chronic disease medication use; states that implemented more protective policies had smaller decreases in enrollment and insignificant decreases in chronic medication use.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This cross-sectional study found that changes in Medicaid medication use during the COVID-19 pandemic continuous enrollment period and after unwinding were smaller than corresponding changes in enrollment. Unwinding had measurable impacts on patient access to prescription medications, but","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e255890"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12761332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Federal Look-Alike Plan Termination Policy and Dual-Eligible Enrollment in Integrated Care Programs.","authors":"Yanlei Ma, Eric T Roberts, Jessica Phelan, Kenton J Johnston, E John Orav, Ellen R Meara, Jose F Figueroa","doi":"10.1001/jamahealthforum.2025.6294","DOIUrl":"10.1001/jamahealthforum.2025.6294","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;In 2023, the Centers for Medicare & Medicaid Services terminated dual-eligible special needs plan look-alikes-Medicare Advantage plans with beneficiary panels composed of more than 80% dual-eligible individuals but lacking Medicaid integration. Understanding whether this policy promoted dual-eligible enrollment in integrated care plans, particularly those attaining high-level integration, is critical.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To describe dual-eligible enrollment transitions after the look-alike plan termination and evaluate whether the policy was associated with increased enrollment in highly integrated plans.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This repeated cross-sectional study analyzed US Medicare administrative data from January 2017 to January 2023. Samples were limited to full-benefit dual-eligible beneficiaries.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;First, a beneficiary-level analysis was conducted on 2023 enrollment patterns among full-benefit dual-eligible individuals whose 2022 plans were terminated, including factors associated with enrollment in highly integrated plans in 2023. Next, a county-year-level difference-in-differences design was used to compare changes in full-benefit dual-eligible enrollment before (2017-2022) and after (2023) the termination policy between counties with vs without terminated look-alike plans. A difference-in-differences design was used to evaluate whether the look-alike termination policy was associated with the proportion of full-benefit dual-eligible individuals enrolled in highly integrated care plans.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Between 2017 and 2022, 482 of 2576 counties had full-benefit dual-eligible individuals enrolled in look-alike plans for at least 1 year. Of the 170 399 full-benefit dual-eligible individuals enrolled in look-alike plans in 2022 (58.9% female; 20.6% Asian, 44.8% Hispanic, 11.3% non-Hispanic Black, 21.4% non-Hispanic White, and 2% other) and remained dual-eligible in 2023, only 5.4% transitioned to highly integrated plans, while 55.6% moved to nonintegrated plans. Dual-eligible individuals transitioning to highly integrated plans were more likely to be older (65-74 years: adjusted difference, 3.4 percentage points [pp]; 95% CI, 2.8-4.1 pp; 75-84 years: adjusted difference, 4.1 pp; 95% CI, 3.3-4.8 pp; ≥85 years: adjusted difference, 5.0 pp; 95% CI, 4.0-5.9 pp), female (adjusted difference: 0.6 pp; 95% CI, 0.2-0.9 pp), without disabilities (adjusted difference, -0.7 pp; 95% CI, -1.2 to -0.2 pp), and less likely to be Asian (adjusted difference, -5.0 pp; 95% CI, -5.6 to -4.4 pp) or Black (adjusted difference, -0.9 pp; 95% CI, -1.6 to -0.2 pp). The termination policy was not associated with a significant differential increase in enrollment into highly integrated plans in counties with look-alike plans compared with those without (0.6 pp; 95% CI, -0.4 to 1.6 pp). However, there was a 2.6-pp differential ","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256294"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12811809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Regulation of Abortion Providers Laws and Pregnancies Conceived Through Fertility Treatment.","authors":"Samuel J F Melville, Jeanne Shi, Bharti Garg, Aaron B Caughey, Molly Kornfield","doi":"10.1001/jamahealthforum.2025.5920","DOIUrl":"10.1001/jamahealthforum.2025.5920","url":null,"abstract":"<p><strong>Importance: </strong>Twenty-seven states have enacted targeted regulation of abortion providers (TRAP) laws that may disproportionately affect higher-risk pregnancies such as those conceived through fertility treatment.</p><p><strong>Objective: </strong>To assess the association of TRAP laws with the relative rates of adverse outcomes of pregnancies conceived through fertility treatment.</p><p><strong>Design, setting, and participants: </strong>This cohort study of singleton births conceived through fertility treatment used National Vital Statistics System data on births between 2012 and 2021. Data were analyzed from August 15, 2024, to September 8, 2025.</p><p><strong>Exposure: </strong>Included participants were categorized as either living under the legal jurisdiction of states with or without TRAP laws enacted during the study period. As laws were not passed in every state uniformly, the first year of enforcement was excluded.</p><p><strong>Main outcomes and measures: </strong>Demographic characteristics of individuals who conceived with fertility treatments living in states with and without TRAP laws were compared using χ2 and analysis of variance tests. A maternal composite of adverse outcomes was constructed. Secondary outcomes included a neonatal composite of adverse outcomes and rate of preterm birth. Controlling for potential confounders, generalized estimating equation models with binomial distribution, identity link, and robust sandwich SE estimators were used to assess adjusted absolute percentage point differences comparing states with and without TRAP laws across the enactment of TRAP laws.</p><p><strong>Results: </strong>This study included 416 019 singleton births (mean [SD] maternal age, 34.5 [5.3] years; mean [SD] gestational age, 38.3 [2.4] weeks; 213 294 males [51.3%]) conceived with fertility treatment. Of these births, 174 671 (42.0%) occurred in states with TRAP laws and 241 348 (58.0%) in states without these laws. Generalized estimating equation models demonstrated a greater increase in the composite of adverse maternal outcomes (absolute adjusted difference-in-differences, 0.25; 95% CI, 0.003-0.50) in states with TRAP laws relative to states without.</p><p><strong>Conclusions and relevance: </strong>These findings suggest an increase in maternal morbidity among patients using fertility care in states that passed TRAP laws relative to states that did not.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e255920"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12789955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145946912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Adoption of Services for Health-Related Social Needs in Medicare.","authors":"Jessica I Billig, Joseph H Joo, Jennifer R Cardin, Michael D Dang, Ching-Ching Claire Lin, Jim P Stimpson, Joshua M Liao","doi":"10.1001/jamahealthforum.2025.6261","DOIUrl":"10.1001/jamahealthforum.2025.6261","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256261"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing the Science and Scholarship of Health Equity.","authors":"Sugy Choi, Ninez A Ponce, Sandro Galea","doi":"10.1001/jamahealthforum.2025.6576","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2025.6576","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"7 1","pages":"e256576"},"PeriodicalIF":11.3,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}